- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05011994
Maintenance of Physical Activity After Cardiac Rehabilitation (FAIR)
Maintenance of Physical Activity After Cardiac Rehabilitation: a Feasibility Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Physical activity is a key element in cardiac rehabilitation and prevention of cardiovascular mortality and hospitalizations. After cardiac rehabilitation programs end, physical activity levels and participation in continued cardiac rehabilitation declines.
The primary aim of this study is to evaluate the feasibility in terms of recruitment, retention, data completeness, intervention delivery and compliance, and acceptability of a mobile health intervention with text messages and behavior change theory in patients with cardiovascular disease for a duration of 3 months after completion of a cardiac rehabilitation program.
The study is a single-group multi-site feasibility trial. Participants will be recruited from phase II cardiac rehabilitation programs at Slagelse Hospital, the city of Slagelse (municipality), and Holbæk Hospital. Starting immediately after completion of cardiac rehabilitation, study participants will receive an intervention that consists of action planning, text messages, and coordinator support for a period of 12 weeks (see more details under 'Arms and Interventions'). The investigators base the intervention on a theoretical model of behavior change in the form of the Health Action Process Approach (HAPA). Behavior change techniques (BCTs) are used as part of the intervention. The intervention is an addition to standard practice and does not replace any existing treatment offers.
To evaluate the feasibility of the intervention and its readiness to be tested in a subsequent RCT design, the investigators have set progression criteria using a system of green (proceed to RCT), amber (amend when proceeding to RCT), or red (issue must be solved before proceeding to RCT). The progression criteria are listed under 'Primary Outcome Measures'.
Participants will wear accelerometers on thigh and wrist for 1 and 3 weeks, respectively, starting 1 week before end of cardiac rehabilitation. Baseline measurements and start of intervention is planned to be at the same time as cardiac rehabilitation ends. After 11 weeks of intervention, participants will attend a follow-up assessment, where participants will wear accelerometers on thigh and wrist again.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rune M Andersen, PhD
- Phone Number: +4558559790 +4529623522
- Email: ruma@regionsjaelland.dk
Study Contact Backup
- Name: Lars H Tang, PhD
- Phone Number: +4558559790
- Email: larta@regionsjaelland.dk
Study Locations
-
-
-
Holbæk, Denmark, 4300
- Recruiting
- Holbæk Hospital
-
Korsør, Denmark, 4220
- Recruiting
- City of Slagelse (municipality)
-
Slagelse, Denmark, 4200
- Recruiting
- Slagelse Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years.
- Participant in an exercise-based cardiac rehabilitation program in either hospital or municipality setting.
- Access to a personal mobile phone and Danish telephone number.
- Able to walk 3 meters without assistance.
Exclusion Criteria:
- Insufficient Danish language proficiency to read and understand text messages and questionnaires.
- Patients cognitively or mentally unable to participate.
- Terminal patients and patients with a life expectancy of less than 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Maintenance intervention
Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
|
The intervention consists of action planning, text messages, and coordinator support. At onset, each participant creates an action plan for physical activity with the help of a health professional:
Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment
Time Frame: Baseline
|
Green: Mean of ≥0.75 recruited participants per week per site Amber: Mean of 0.5-0.74 recruited participants per week per site Red: Mean of <0.5 recruited participants per week per site |
Baseline
|
Attrition/retention through follow-up assessment session
Time Frame: Up to 12 weeks
|
Green: ≥80% retention of participants through follow up Amber: 50-79% retention of participants through follow up Red: <50% retention of participants through follow up |
Up to 12 weeks
|
Accelerometer data completeness
Time Frame: Baseline
|
Green: Accelerometer data from both baseline and follow-up available on ≥80% of completing participants Amber: Data available on 50-79% of completing participants Red: Data available on <50% of completing participants |
Baseline
|
Accelerometer data completeness
Time Frame: 12 weeks
|
Green: Accelerometer data from both baseline and follow-up available on ≥80% of completing participants Amber: Data available on 50-79% of completing participants Red: Data available on <50% of completing participants |
12 weeks
|
Response rate on patient reported outcomes
Time Frame: Baseline
|
Green: ≥90% of participants attending baseline and follow-up assessment return patient reported outcomes Amber: 75-89% of patients attending baseline and follow-up assessment return patient reported outcomes Red: <75% of participants attending baseline and follow-up assessment return patient reported outcomes |
Baseline
|
Response rate on patient reported outcomes
Time Frame: 12 weeks
|
Green: ≥90% of participants attending baseline and follow-up assessment return patient reported outcomes Amber: 75-89% of patients attending baseline and follow-up assessment return patient reported outcomes Red: <75% of participants attending baseline and follow-up assessment return patient reported outcomes |
12 weeks
|
Coordinator time spent, minutes per participant throughout the intervention
Time Frame: 12 weeks
|
Green: Mean coordinator time spent of ≤30 minutes per participant Amber: Mean coordinator time spent of 31-60 minutes per participant Red: Mean coordinator time spent of >60 minutes per participant |
12 weeks
|
Response rate (adherence) to weekly follow-up messages
Time Frame: 12 weeks
|
Green: ≥75% of patients respond to at least 75% of messages Amber: 50-74% of patients respond to at least 75% of messages Red: <50% of patients respond to at least 75% of messages |
12 weeks
|
Acceptability of text message component, single item
Time Frame: 12 weeks
|
Green: ≥75% of participants find text messages acceptable Amber: 50-74% of participants find text messages acceptable Red: <50% of participants find text messages acceptable |
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity, objectively measured
Time Frame: Change from baseline to 12 weeks
|
Measured with thigh and wrist accelerometers
|
Change from baseline to 12 weeks
|
Physical function, walking
Time Frame: Change from baseline to 12 weeks
|
6 minute walking test
|
Change from baseline to 12 weeks
|
Physical function, sit-to-stand
Time Frame: Change from baseline to 12 weeks
|
30-second sit-to-stand test
|
Change from baseline to 12 weeks
|
Physical activity, subjectively measured
Time Frame: Change from baseline to 12 weeks
|
The International Physical Activity Questionnaire (IPAQ) is used to measure physical activity in the past 7 days.
0 is minimum (completely inactivty).
|
Change from baseline to 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life, general
Time Frame: Change from baseline to 12 weeks
|
EQ-5D-5L evaluates health status in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is rated from 1 (best) to 5 (worst) and overall health is rated on a 0 to 100 VAS scale.
|
Change from baseline to 12 weeks
|
Health-related quality of life, VAS subscale
Time Frame: Change from baseline to 12 weeks
|
EQ-5D-5L evaluates health status in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is rated from 1 (best) to 5 (worst) and overall health is rated on a 0 to 100 VAS scale.
|
Change from baseline to 12 weeks
|
Health-related quality of life, heart-specific
Time Frame: Change from baseline to 12 weeks
|
HeartQoL is used to measure heart-specific quality of life in the past 4 weeks.
Range from 0 (worst) to 42 (best) .
|
Change from baseline to 12 weeks
|
Anxiety and depression
Time Frame: Change from baseline to 12 weeks
|
Hospital Anxiety and Depression Scale (HADS).
HADS gives a score for each of anxiety and depression, each ranging from 0 (best) to 21 (worst).
|
Change from baseline to 12 weeks
|
Physical function, self-reported
Time Frame: Change from baseline to 12 weeks
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2.0),12-item version.
WHODAS is a generic assessment instrument for health and disability.
Range from 12 (no disability) to 60 (highest disability or loss of function).
|
Change from baseline to 12 weeks
|
Comorbidity
Time Frame: Change from baseline to 12 weeks
|
Disease Burden: Morbidity Assessment by Self-Report used to evaluated a list of common chronic conditions affect the participants' daily activities.
Each condition (that the participant has) is rated from 1 (not at all) to 5 (a lot) in regard to how much it limits daily activities.
|
Change from baseline to 12 weeks
|
Self-efficacy, managing chronic disease
Time Frame: Change from baseline to 12 weeks
|
Self-efficacy of managing chronic disease 6 items scale.
Score is calculated as the mean of 6 items, each scored from 1 (low self-efficacy) to 10 (high self-efficacy).
|
Change from baseline to 12 weeks
|
Motivational Self-efficacy
Time Frame: Change from baseline to 12 weeks
|
Motivational self-efficacy, HAPA items by Schwartzer R., 2 items each rated on a scale from 1 (low self-efficacy) to 4 (high self-efficacy).
|
Change from baseline to 12 weeks
|
Coping Self-efficacy
Time Frame: Change from baseline to 12 weeks
|
Coping self-efficacy, HAPA items by Schwartzer R., 2 items each rated on a scale from 1 (low self-efficacy) to 4 (high self-efficacy).
|
Change from baseline to 12 weeks
|
Recovery Self-efficacy
Time Frame: Change from baseline to 12 weeks
|
Recovery self-efficacy, HAPA items by Schwartzer R., 2 items each rated on a scale from 1 (low self-efficacy) to 4 (high self-efficacy).
|
Change from baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rune M Andersen, PhD, Næstved-Slagelse-Ringsted Hospitals; University of Southern Denmark
- Study Chair: Lars H Tang, PhD, Næstved-Slagelse-Ringsted Hospitals; University of Southern Denmark
- Study Chair: Søren T Skou, PhD, Næstved-Slagelse-Ringsted Hospitals; University of Southern Denmark
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMN-2021-00020 (Other Identifier: Research Ethics Committee of Region Zealand, Denmark)
- REG-162-2020 (Other Identifier: Danish Data Protection Agency through Region Zealand)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Foundation IRCCS San Matteo HospitalFondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaboratorsWithdrawnST-elevation Myocardial InfarctionItaly
Clinical Trials on Maintenance intervention
-
Vanderbilt University Medical CenterRecruitingBreast CancerUnited States
-
VA Office of Research and DevelopmentCompletedObesity, MorbidUnited States
-
University of CalgaryAlberta Cancer FoundationCompleted
-
Technical University of MunichActive, not recruiting
-
University of HawaiiQueen's Medical Center; I Ola Lahui, Inc.; Ke Ola Mamo; Queen Lili'uokalani Children... and other collaboratorsCompletedObesity | Overweight | Weight Loss | Weight Loss MaintenanceUnited States
-
University of Massachusetts, BostonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedObesityUnited States
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); American Heart AssociationCompletedPhysical Activity | Sedentary LifestyleUnited States
-
Sinai Health SystemUnknown
-
University of California, Los AngelesCompleted
-
University of Texas Southwestern Medical CenterCompletedHypertension | Obesity | Cardiovascular Disease | DiabetesUnited States